U.S. market Closed. Opens in 6 hours 7 minutes

MLAB | Mesa Laboratories, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 116.70 - 120.06
52 Week Range 82.86 - 141.17
Beta 0.55
Implied Volatility N/A
IV Rank N/A
Day's Volume 34,708
Average Volume 31,879
Shares Outstanding 5,409,160
Market Cap 640,715,002
Sector Technology
Industry Hardware, Equipment & Parts
IPO Date 1984-02-29
Valuation
Profitability
Growth
Health
P/E Ratio -2.55
Forward P/E Ratio N/A
EPS -46.48
1YR Price Target N/A
Dividend Yield 0.56%
Dividend Per Share 0.66
Dividend ExDate N/A
Dividend PayDate N/A
Employees 736
Country USA
Website MLAB
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
MLAB's peers: BMI, CGNX, SOTK, CPTN, ELSE, ESE, FCUV, FARO, FTV, GNSS, ITRI, LUNA, MIND, MKSI, NOVT, VPG, COHR, ST, SEPJF, VNT, TCX, TDY, WINA
*Chart delayed
Analyzing fundamentals for MLAB we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see MLAB Fundamentals page.

Watching at MLAB technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on MLAB Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙